Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales [Yahoo! Finance]
Emergent Biosolutions, Inc. (EBS)
Last emergent biosolutions, inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Yahoo! Finance
In the year-ago quarter, EBS reported adjusted earnings of 11 cents per share. Revenues in the quarter totaled $276.6 million, down 16% from the prior-year period's level. The reported figure outpaced the Zacks Consensus Estimate of $247.6 million. The company's shares lost almost 16% in after-market trading on Mar 6, likely due to the earnings miss. The stock has surged 35.8% in the year-to-date period compared with the industry's 2.8% growth. Image Source: Zacks Investment Research Quarter in Detail Total product sales were down 19% from the year-ago quarter's level to $249.1 million. Sales of Anthrax Medical Counter measures (Anthrax MCM), comprising of Cyfendus (previously known as AV7909), BioThrax, Anthrasil and raxibacumab, totaled $111.6 million in the reported quarter, up 98% year over year. The upside can be attributed to the favorable timing of sales related to Cyfendus, Anthrasil and BioThrax. Narcan (naloxone HCl) nasal spray added $111.0 million to produc
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent Biosolutions, Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- FDA approves Amneal's generic version of OTC Narcan [Seeking Alpha]Seeking Alpha
- Ascend Hires Scott Law as COO and Continues Strengthening Foundation [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024GlobeNewswire
- Institutional owners may take dramatic actions as Emergent BioSolutions Inc.'s (NYSE:EBS) recent 16% drop adds to one-year losses [Yahoo! Finance]Yahoo! Finance
EBS
Earnings
- 3/6/24 - Miss
EBS
Sec Filings
- 4/26/24 - Form 8-K
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- EBS's page on the SEC website